secwatch.observer — SEC 8-K summary
======================================

Issuer:     Enliven Therapeutics, Inc. (ELVN)
CIK:        0001672619
Form:       8-K
Filed at:   2021-07-13T23:59:59+00:00
Accession:  0001193125-21-214102
Event type: other_material
Sentiment:  neutral
Materiality: 0.10
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

IMARA files July 2021 corporate presentation on hemoglobin disorder pipeline
----------------------------------------------------------------------------

- Filed a corporate slide presentation as Exhibit 99.1 under Item 8.01.
- Presentation titled 'Advancing Novel Treatments for Hemoglobin Disorders' dated July 2021.
- No financial results, guidance, or material operational updates provided.
- Routine disclosure of materials used in investor meetings; no new events announced.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1672619/000119312521214102/0001193125-21-214102-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1672619/000119312521214102/d150922d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-214102

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer